Technologies

Pluripotent Cells

Pluripotent Cells Portfolios

Most Recent Inventions

Xeno-Free Protocol for Generating Endothelial Cells from Human Pluripotent Stem Cells

UW–Madison researchers have developed a fully defined and xenogenic material-free method of producing and expanding clinically relevant human ECs for therapeutic and tissue modelling applications. Populations of up to 80 percent CD31+ ECs are generated from both human embryonic and induced pluripotent stem cells.

Like existing protocols, the new method uses factors including Bone Morphogenetic Protein (BMP), Activin A and a TGF-Beta 1 inhibitor.
P140372US02

Human Pluripotent Stem Cell-Based Models for Neural Toxicity Screening

UW–Madison researchers have developed 3-D vascularized neuronal tissue models for screening neurotoxic agents. The new constructs are highly uniform and the first to contain every major component of the developing brain: neuronal cells (GABAergic and Glutamatergic), glial cells (astrocytes and oligodendrocytes), interconnected vasculature and mature microglia.

Combined with the modular nature of tunable hydrogels and the power of machine learning tools, the new testing platform enables large-scale, quantitative throughput applications.
P140400US02

Derivation of Human Microglia from Pluripotent Stem Cells

UW–Madison researchers have discovered a primitive, macrophage-like cell type of the hematopoietic lineage that has the capability to develop ramified human microglia when added to a neural tissue construct. Accordingly, they have developed the first known protocol of its kind for differentiating and expanding microglia suitable for clinically relevant therapeutic applications.
P140410US02

Mesenchymal Stem Cell-Educated Macrophages to Treat Radiation Damage and More

UW–Madison researchers have discovered that mesenchymal stem cell-educated macrophages (MEMs) have potent tissue regenerative properties that can minimize tissue damage from radiation and increase survival in clinically significant ways.

They have demonstrated in a relevant preclinical model that their new method is much superior to other forms of cellular therapy, including use of mesenchymal stem cells, for preventing and treating radiation-induced morbidity and mortality, GVHD and other conditions associated with uncontrolled inflammation. They purport that allogenic or autologous MEMs can be administered to exposed or damaged organs to treat acute, subacute or chronic radiation-induced disorder.
P140399US02

Generating Human Heart Cells via Lineage Reprogramming

UW–Madison researchers have developed a method to reprogram human (or other mammalian) somatic cells to iCPCs by defined factors. The factors include several early cardiac transcription factors and a chromatin remodeling factor. They may be introduced into the cell via standard vector techniques. Successfully reprogrammed cells are separated from the others and cultured in a proliferative state.
P140116US02

Most Recent Patents

Polymer Coating for Cell Culture Substrates

UW–Madison researchers have developed a new crosslinkable polymer coating for cell culture substrates. The nanometer-thin coating is made of glycidyl groups and azlactone groups distributed randomly along the copolymer backbone.

The coating is substrate independent and can be applied to a wide variety of organic and inorganic materials including plastic, silicon, glass and gold.
P150079US01

Albumin-Free Protocol Cuts Cost, Supports Large-Scale Cardiomyocyte Production

UW–Madison researchers have developed a method for generating high yield, high purity cardiomyocytes/progenitors from PSCs under defined, albumin-free conditions. Their discovery that albumin is not necessary, and may even be deleterious, for cardiomyocyte differentiation dramatically reduces the cost of production.
P150011US02

Hydrogel Arrays for Screening Cell-Substrate Interactions, Now in Multiwell Format

Building on their previous work, the researchers have now adapted their method to any commercially available, glass or polystyrene-bottom multiwell plate. In the new process, hydrogel is covalently immobilized to the bottom of each well and then selectively polymerized. In this way the spots are completely isolatable, allowing for systemic and independent control of their chemical composition and XYZ physical dimensions.

Once the hydrogel array is formed, each of the spots can be exposed to different soluble factors without risk of diffusion.
P140305US01